Author | Year | Country | Group | No. of patients | M/F | Age, year (range and/or SD) | MH | Tumor size, cm (range and/or SD) | No. of tumor (range and/or SD) | Conversions (n [%]) | Study quality |
---|---|---|---|---|---|---|---|---|---|---|---|
Mala et al. [9] | 2002 | Norway | LLR | 13 | 4/9 | 68 (55–73) | 2 | 2.6 (1–6) | 2 (1–7) | 0 | ***** |
OLR | 14 | 4/10 | 59 (24–74) | 2 | 3 (1.5-9) | 1 (1–4) | |||||
Castaing et al.[10] | 2009 | France | LLR | 60 | 37/23 | 62 ± 11 | 26 | 3.3 ± 1.1 | 2.2 ± 2.3 | 6 (10) | ******* |
OLR | 60 | 37/23 | 62 ± 11 | 24 | 4.4 ± 3.8 | 2.2 ± 1.98 | |||||
Abu et al. [11] | 2010 | United Kingdom | LLR | 50 | 28/22 | 66 (42–85) | 19 | 3.15 (0.3–9) | 1 (1–3) | 6 (12) | ****** |
OLR | 85 | 55/30 | 67 (47–86) | 46 | – | – | |||||
Cheung et al. [12] | 2012 | Hong Kong | LLR | 20 | 13/7 | 57.5 (42–74) | 1 | 1.5 (0.5–4.5) | 1 (1–2) | 0 | ******* |
OLR | 40 | 29/11 | 64 (29–83) | 2 | 2.2 (0.5–7) | 1 (1–2) | |||||
Cannon et al. [13] | 2012 | United States | LLR | 35 | – | 62 ±10 | 19 | 4 ±3 | 1 ± 1 | – | ******* |
OLR | 138 | – | 62 ±11 | 71 | 5 ± 3 | 1 ± 1 | |||||
Topal et al. [14] | 2012 | Belgium | LLR | 20 | 10/10 | 57.6 | 20 | 4 (0.4–7) | 2 (1–6) | – | ****** |
OLR | 20 | 8/12 | 66.0 | 20 | 3.2 (1–12.5) | 2 (1–14) | |||||
Guerron et al. [15] | 2013 | United States | LLR | 40 | 21/19 | 66.2 ± 1.9 | 5 | 3.3 ± 0.3 | 1.3 ± 0.1 | 2 (5) | ******* |
OLR | 40 | 15/25 | 62.2 ± 1.8 | 9 | 3.2 ± 0.3 | 1.7 ± 0.1 | |||||
Qiu et al. [16] | 2013 | China | LLR | 30 | 14/16 | 52.5 ± 11.5 | 2 | 2.5 ± 2.0 | ≥2 (n=10) | 2 (6.6) | ******** |
 |  |  | OLR | 30 | 15/15 | – | 5 | 2.8 ± 1.5 | ≥2 (n=9) |  |  |